3920.F Spyre Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
93.00 EUR
Close of Nov 11, 2026
19.20 96.00
Market cap
EUR 8.83B
P/E
-
P/B
10.70x
ROE
-25.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 3920.F undervalued?

Graham number

The Graham number of Spyre Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spyre Therapeutics, Inc. fundamental analysis

No fundamental analysis for Spyre Therapeutics, Inc. yet.

Spyre Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to…

Full company profile